Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice
Key claim: Rapamycin therapeutically reprograms immune responses to attenuate atherosclerotic plaque inflammation and lymphoid immune activity in aged mice.
Abstract
Aging Cell, Volume 25, Issue 10, October 2026.
Why this matters
Rapamycin’s aging-mechanism narrative has centered on cellular growth control, autophagy, and senescence; this study operationalizes a distinct arm — therapeutic reprogramming of aged adaptive immunity at the atherosclerotic plaque — inside a disease-relevant aged model. It extends the mTOR-inhibition-as-geroprotection story into cardiovascular immunopathology but keeps the evidence squarely preclinical, without translating the immune-reprogramming claim to human plaque or cardiovascular event endpoints.